14M111: Updated American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-induced Osteoporosis

Monday, November 14, 2022

9:00 AM – 10:00 AM Eastern Time

Location: Ballroom AB

CE: 1

All of the relevant financial relationships listed for faculty have been mitigated.

Moderator(s)

JC

Julia Charles, MD, PhD

Brigham and Women's Hospital
Boston, MA, United States

Disclosure(s): Ultragenyx: Advisor or Review Panel Member (Ongoing)
Jonathan Cheah, MBBS

UMass Chan Medical School
Shrewsbury, MA, United States

Disclosure(s): No financial relationships with ineligible companies to disclose

This session will review the updated ACR guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis. This guideline was last updated in 2017. The current guideline addresses all the currently FDA- approved medications for osteoporosis and the use of these medications for the treatment of glucocorticoid- induced osteoporosis.

Additionally, the use of combination therapy and sequential therapy will be reviewed. We will also demonstrate the application of this guideline in clinical case scenarios.

Learning Objectives:

Apply the recommendations for fracture risk assessment and reassessment in glucocorticoid-induced osteoporosis
Explain when to prescribe calcium, vitamin D, and lifestyle modifications
Identify patients who warrant consideration for pharmacologic therapy and recognize the relative benefits and harms of pharmacologic therapies to prevent fracture

Presentations:

9:00 AM – 9:20 AM Eastern Time

GIOP Guideline: An Overview
Speaker: Mary Beth Humphrey, MD, PhD – University of Oklahoma Health Sciences Center
9:20 AM – 9:40 AM Eastern Time

GIOP Guideline: Case-Based Applications
Speaker: Linda Russell, MD – Hospital for Special Surgery
9:40 AM – 10:00 AM Eastern Time

Q&A